<DOC>
	<DOCNO>NCT00864994</DOCNO>
	<brief_summary>There increase evidence literature COPD consider localised pulmonary disorder systemic disease involve pathology several extra pulmonary tissue . Well characterized systemic feature chronic low grade systemic inflammation , alter body composition skeletal muscle fibre type shift . There indication absolute relative increase fat mass put COPD patient increase risk cardiovascular pathology muscle atrophy associate high prevalence osteoporosis impair physical function . The origin systemic inflammation poorly understood . Both endogenous exogenous risk factor contribute systemic inflammation extra-pulmonary manifestation COPD . Overall objective study 3 : To compare pattern severity systemic inflammatory profile relation skeletal muscle weakness cardiovascular risk profile COPD patient mild moderate disease compare non-susceptible smoker . Specific objective : 1 . To study relative contribution pulmonary extra pulmonary factor exercise capacity , skeletal muscle function health status 2 . To relate diet , physical activity cardiovascular risk factor body composition , skeletal muscle function exercise capacity status 3 . To study influence emphysema phenotype extra pulmonary pathology COPD 4 . To study muscle fibre type size composition relate muscle oxidative phenotype insulin sensitivity , inflammation ( local systemic ) molecular signature oxidative energy protein metabolism . Study design : Cross-sectional study . Healthy smoke subject COPD patient undergo extensive clinical , metabolic inflammatory assessment university clinic Groningen , Maastricht CIRO Horn . Study population : Totally 60 subject include - 30 healthy subject 20 pack year smoke sign COPD ( age 40-75 year ) - 30 COPD patient GOLD stage II ( age 40-75 year )</brief_summary>
	<brief_title>Multiorgan Pathology Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Primary study parameters/outcome study : 1 . Smoking history behaviour , diet physical activity level assess questionnaire 2 . Extensive lung function CT scanning lung , ECG 3 . Candidate gene muscle dysfunction CVD risk 4 . Body composition ( BIA , waist-hip ratio , DEXA-scan ) 5 . Systemic inflammation 6 . Advanced Glycosylated Endproduct ( AGE ) 7 . Glucose tolerance test 8 . Risk factor metabolic syndrome 9 . 6 minute walk distance 10 . Handgrip strength 11 . Skeletal muscle function isokinetic dynamometry 12 . Physical activity level pattern accelerometry 13 . Muscle oxidative phenotype , fibre cross-sectional area molecular signature obtain vastus lateralis muscle biopsy incremental cycle ergometry Nature extent burden risk associate participation , benefit group relatedness ( applicable ) : - Totally 22 hour spend hospital 3 visit - CT-scanning lung associate radiation burden 0.8-1.6 mSv ( dependent body weight ) - 50 ml peripheral blood ( v. cubiti ) - Muscle biopsy may associate temporary pain haematoma - Drawing arterial blood radial artery rarely lead bleed transitory nerve damage ( numb feeling wrist/hand area ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Age 4075 year Age , pack year , FEV1/FVC FEV1 % predict must fit one 2 group table 4.3 Physically mentally able undergo total study protocol Written inform consent Participation another study Alpha1antitrypsin deficiency Selected grade 13 comorbidity list ACE27 Active pulmonary infection like tuberculosis , pneumonia , flue , tracheobronchitis Active extrapulmonary infection like hepatitis AC , cystitis , gastroenteritis etc . Pulmonary disease like sarcoidosis , IPF , silicosis , hypersensitivity pneumonitis , asthma Life threaten disease like carcinoma , AIDS ( include HIV+ ) , acute leukemia etc . Medication may affect result study : NSAID 's , immunosuppressive agent like prednisolon , methotrexate , azathioprine , sintrom tablet , askal Antibiotic prednisolon use past 2 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>COPD</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Smoking</keyword>
	<keyword>Multiorgan pathology</keyword>
	<keyword>Extra pulmonary manifestation</keyword>
</DOC>